Moderna Announces First Data Showing Efficacy of COVID-19 Vaccine Booster in Development

May 7, 2021

(Medscape) – The Moderna SARS-CoV-2 vaccine booster developed specifically with variant B.1.351 in mind shows efficacy against that strain and the P1 variant among people already vaccinated for COVID-19, according to first results released on Wednesday. Furthermore, data from the company’s ongoing phase 2 study shows the variant-specific booster, known as mRNA-1273.351, achieved higher antibody titers against the B.1.351 variant than a booster with the original Moderna vaccine.